Meanwhile, there was bad blood between cell therapy players and their investors.
Promising but early data with OTL-201 could see the group compete against the likes of Ultragenyx and Lysogene.
Vyvgart gets a prestigious press slot for its next potential use, while Sangamo’s haemophilia A gene therapy mimics Biomarin’s valrox again.
But, with Applied Genetic Technologies Corporation, can lightning strike a third time?
Bluebird’s gene therapy is to be launched in the US priced $2.8m per patient, but can the company tread the cautious path to profitability?
Fibrogen’s controversial anaemia pill becomes the latest example of markedly different regulatory stances taken in Europe and the US.